- Home
- ALTS vs NRXP Comparison
ALTS vs NRXP Comparison
Compare ALTS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- NRXP
- Stock Information
- Founded
- ALTS 1976
- NRXP 2015
- Country
- ALTS United States
- NRXP United States
- Employees
- ALTS N/A
- NRXP N/A
- Industry
- ALTS
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- ALTS
- NRXP Health Care
- Exchange
- ALTS NYSE
- NRXP Nasdaq
- Market Cap
- ALTS 26.0M
- NRXP 21.6M
- IPO Year
- ALTS N/A
- NRXP N/A
- Fundamental
- Price
- ALTS $1.80
- NRXP $1.53
- Analyst Decision
- ALTS
- NRXP Strong Buy
- Analyst Count
- ALTS 0
- NRXP 2
- Target Price
- ALTS N/A
- NRXP $31.50
- AVG Volume (30 Days)
- ALTS 218.9K
- NRXP 95.0K
- Earning Date
- ALTS 11-12-2024
- NRXP 11-12-2024
- Dividend Yield
- ALTS N/A
- NRXP N/A
- EPS Growth
- ALTS N/A
- NRXP N/A
- EPS
- ALTS N/A
- NRXP N/A
- Revenue
- ALTS $2,169,000.00
- NRXP N/A
- Revenue This Year
- ALTS N/A
- NRXP N/A
- Revenue Next Year
- ALTS N/A
- NRXP N/A
- P/E Ratio
- ALTS N/A
- NRXP N/A
- Revenue Growth
- ALTS N/A
- NRXP N/A
- 52 Week Low
- ALTS $0.22
- NRXP $1.49
- 52 Week High
- ALTS $5.26
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- ALTS 41.37
- NRXP 36.03
- Support Level
- ALTS $1.70
- NRXP $1.59
- Resistance Level
- ALTS $1.89
- NRXP $1.67
- Average True Range (ATR)
- ALTS 0.15
- NRXP 0.10
- MACD
- ALTS -0.02
- NRXP 0.00
- Stochastic Oscillator
- ALTS 19.61
- NRXP 12.94
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.